Date: 2015-12-21
Type of information: Nomination
Compound:
Company: NovImmune (Switzerland)
Therapeutic area: Rare diseases - Immunological diseases - Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On December 21, 2015, Novimmune announced that the Board of Directors at its meeting of December 16, 2015 appointed Ed Holdener as Chief Executive Officer of the Company, effective immediately. This decision comes following a series of significant advances in the clinical development, as well as scientific validation, of Novimmune’s lead compound NI-0501. In order to best capitalize on the positive momentum leading to a possible trade sale or an IPO of parts or all of the Company, Ed Holdener will serve as Chairman as well as CEO of Novimmune S.A. Prior to joining Novimmune, Ed Holdener was Chief Medical Officer of Roche. The Board of Directors would like to thank Jack Barbut for his stewardship during the past 15 years. Jack will stay on as Board Member until the next ordinary shareholders’ meeting.
Financial terms:
Latest news:
